Innoviva Inc. Stock
Price
Target price
€15.20
€15.20
-4.400%
-0.7
-4.400%
€22.27
01.10.25 / Stuttgart Stock Exchange
WKN: A2AC9U / Symbol: INVA / Name: Innoviva / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Innoviva Inc. Stock
Innoviva Inc. took a tumble today and lost -€0.700 (-4.400%).
Our community is currently high on Innoviva Inc. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 22 € shows a positive potential of 44.74% compared to the current price of 15.2 € for Innoviva Inc..
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | -4.400% | -4.403% | -11.111% | -12.644% | -7.879% | 31.034% | 78.824% |
| Pacira Pharmaceuticals | 0.940% | -1.835% | -3.604% | 57.353% | 15.676% | -60.000% | -57.200% |
| Rockwell Medical Inc. | -6.000% | -5.472% | -32.977% | -69.728% | -50.298% | -24.091% | -89.707% |
| Twist Bioscience Corp | 4.960% | 8.380% | 9.908% | -36.375% | -45.419% | -30.638% | -62.466% |
Comments
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (NASDAQ:INVA) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva (INVA) Q2 Sales Jump 64%
Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share
